2025-12-07 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the provided data.

**1. Return Rate Comparison**

*   **Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation systems for transplantation.
*   **TMDX Cumulative Return:** 244.80%
*   **S&P 500 (VOO) Cumulative Return:** 76.52%
*   **Divergence:** 186.2 (Relative Divergence: 81.0)

**Analysis:** TMDX has significantly outperformed the S&P 500 over the period examined. The divergence of 186.2 indicates a substantial difference in cumulative returns. The relative divergence of 81.0 suggests that this divergence is high compared to its historical fluctuations.

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|-----------|--------|-------|--------|------|--------|
| 2019-2021 | -18.0% | 83.5% | -61.0% | -0.0 | 0.6    |
| 2020-2022 | 94.0%  | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023 | 65.0%  | 80.5% | 64.0%  | 0.1  | 2.6    |
| 2022-2024 | 130.0% | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025 | 166.0% | 85.5% | 100.0% | 0.3  | 4.7    |

*   **CAGR (Compound Annual Growth Rate):** TMDX has demonstrated strong growth in recent periods (2020-2025), with the highest CAGR of 166.0% in the most recent period.
*   **MDD (Maximum Drawdown):** MDD is consistently high, indicating significant volatility and risk.
*   **Alpha:** Positive Alpha indicates that TMDX has consistently outperformed its benchmark index on a risk-adjusted basis.
*   **Beta:** A low Beta suggests that TMDX has historically been less sensitive to market movements than the S&P 500, although it has increased in the most recent year.
*   **Cap(B):** The company's market capitalization has generally increased over time, suggesting growing investor confidence.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 140.10
*   **Last Market Data:** Price: 136.51, Previous Close: 138.63, Change: -1.53
*   **5-day SMA:** 143.71
*   **20-day SMA:** 129.32
*   **60-day SMA:** 122.55

**Analysis:** The stock price is currently below its 5-day SMA, suggesting a recent short-term pullback. However, it remains above both the 20-day and 60-day SMAs, indicating an overall upward trend over the medium and longer terms. The negative change in the last market price reflects a recent decline.

**3. Indicators Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 66.17
*   **PPO (Percentage Price Oscillator):** 1.14
*   **Hybrid Signal:** 100% Buy recommendation, with a small monthly investment suggested.
*   **Recent Divergence Change:** 14.5 (+), indicating a short-term increase.
*   **Expected Return:** 30.0% (Excess return compared to S&P 500 for long-term investment)

**Analysis:** The MRI suggests a medium investment recommendation. The RSI of 66.17 is approaching overbought levels (above 70), but not quite there yet. The positive PPO indicates an upward trend. The hybrid signal reinforces the buy recommendation. The recent increase in relative divergence aligns with the positive PPO.

**4. Recent News & Significant Events**

*   **Positive Headlines:** Several articles highlight TMDX as a top growth stock for the long term.
*   **Institutional Investment:** Marshall Wace LLP increased its stake in TMDX.
*   **Executive Stock Sales:** Reports indicate that top executives at TransMedics Group have made significant stock sales.
*   **Dividend Sustainability:** An article discusses the sustainability of TMDX's dividend payout.
*   **Valuation Evaluation:** An article evaluates TMDX's valuation after strong year-to-date gains.

**Analysis:** The news is a mixed bag. The positive headlines and institutional investment are bullish signals. However, the executive stock sales could raise concerns about insider confidence, although it could also be for personal financial reasons. The articles on dividend sustainability and valuation suggest that analysts are scrutinizing the company's fundamentals.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (Buy)
*   **Opinions:** 11
*   **Target Price (avg/high/low):** 143.00 / 170.00 / 114.00
*   **Recent Rating Changes:** No recent changes listed

**Analysis:** Analyst consensus is positive, with a Buy rating and a target price suggesting moderate upside potential from the current price. The absence of recent rating changes suggests a stable outlook from analysts.

**5. Comprehensive Analysis**

TransMedics Group (TMDX) has demonstrated strong growth and significantly outperformed the S&P 500. The company exhibits high volatility (MDD), but also generates substantial Alpha, indicating a capacity to deliver risk-adjusted returns. Recent stock performance shows a short-term pullback, but the overall trend remains upward.

The MRI and analyst consensus point toward a buy recommendation. However, potential investors should be aware of the high MDD, implying substantial risk.

The recent news presents a mixed picture. While positive articles and increased institutional ownership are encouraging, the executive stock sales warrant further investigation. The articles discussing dividend sustainability and valuation highlight the importance of carefully evaluating the company's fundamentals.

**In summary, TMDX appears to be a growth stock with significant potential, but also considerable risk. Investors should conduct thorough due diligence and carefully consider their risk tolerance before investing.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.